you get 18-25% proteinuria reduction on sparsentan over active control from ~400 pts across 2 trials vs 17% for DMX-200 from a study of 8 pt. doesn't exactly create confidence. Also no mention of complete responses on DMX-200 (saw a benefit there from sparsentan). Context is sparsentan is having trouble getting approved on these decent surrogate endpoints, and no stat.sig effect on eGFR. Tough market. but even tougher crowd on HotCopper!
Ann: Dimerix Presents at ASX Small & Mid-Cap Conference, page-49
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
0.035(7.37%) |
Mkt cap ! $280.6M | |||
| Open | High | Low | Value | Volume |
| 47.5¢ | 54.0¢ | 47.5¢ | $3.360M | 6.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25428 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.5¢ | 15478 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |